IMerge

BTIG expects Geron Corporation (NASDAQ: GERN) shares to be range-bound until major data release, potentially in late 2017 or 2018. Geron's lead compound imetelstat, an inhibitor of telomerase partnered with Johnson & Johnson (NYSE: JNJ)'s Janssen showed impressive activity in multiple...